652 related articles for article (PubMed ID: 25973084)
21. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
22. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
[TBL] [Abstract][Full Text] [Related]
23. IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Fuchs CS; Ogino S
Neoplasia; 2007 Dec; 9(12):1091-8. PubMed ID: 18084616
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
26. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.
Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Kirkner GJ; Dehari R; Meyerhardt JA; Fuchs CS; Ogino S
Neoplasia; 2007 Jul; 9(7):569-77. PubMed ID: 17710160
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
Ogino S; Kawasaki T; Kirkner GJ; Kraft P; Loda M; Fuchs CS
J Mol Diagn; 2007 Jul; 9(3):305-14. PubMed ID: 17591929
[TBL] [Abstract][Full Text] [Related]
28. The role of the CpG island methylator phenotype on survival outcome in colon cancer.
Kang KJ; Min BH; Ryu KJ; Kim KM; Chang DK; Kim JJ; Rhee JC; Kim YH
Gut Liver; 2015 Mar; 9(2):202-7. PubMed ID: 25167802
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.
Rhee YY; Kim MJ; Bae JM; Koh JM; Cho NY; Juhnn YS; Kim D; Kang GH
Ann Surg Oncol; 2012 Oct; 19(11):3441-8. PubMed ID: 22618722
[TBL] [Abstract][Full Text] [Related]
30. Annexin A10 expression correlates with serrated pathway features in colorectal carcinoma with microsatellite instability.
Kim JH; Rhee YY; Kim KJ; Cho NY; Lee HS; Kang GH
APMIS; 2014 Dec; 122(12):1187-95. PubMed ID: 24909058
[TBL] [Abstract][Full Text] [Related]
31. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
[TBL] [Abstract][Full Text] [Related]
32. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
33. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.
Ogino S; Nosho K; Irahara N; Meyerhardt JA; Baba Y; Shima K; Glickman JN; Ferrone CR; Mino-Kenudson M; Tanaka N; Dranoff G; Giovannucci EL; Fuchs CS
Clin Cancer Res; 2009 Oct; 15(20):6412-20. PubMed ID: 19825961
[TBL] [Abstract][Full Text] [Related]
34. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
Kim CH; Huh JW; Kim HR; Kim YJ
J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
[TBL] [Abstract][Full Text] [Related]
35. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Ogino S; Brahmandam M; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
Neoplasia; 2006 Jun; 8(6):458-64. PubMed ID: 16820091
[TBL] [Abstract][Full Text] [Related]
36. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
Bettstetter M; Woenckhaus M; Wild PJ; Rümmele P; Blaszyk H; Hartmann A; Hofstädter F; Dietmaier W
J Pathol; 2005 Apr; 205(5):606-14. PubMed ID: 15714592
[TBL] [Abstract][Full Text] [Related]
37. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Firestein R; Baba Y; Toyoda S; Chen L; Hazra A; Giovannucci EL; Fuchs CS; Ogino S
Mod Pathol; 2009 Jul; 22(7):922-32. PubMed ID: 19430421
[TBL] [Abstract][Full Text] [Related]
38. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS
Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756
[TBL] [Abstract][Full Text] [Related]
39. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
[TBL] [Abstract][Full Text] [Related]
40. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
